UNSPSC 51282940: Premafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C21H26FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOM2HMO524, chemically known as 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(1-(methylamino)ethyl)-1-pyrrolidinyl)-4-oxo-, (s-(r*,s*))- but generally known as premafloxacin, which bears US NIH Compound Identifier 71455. European Medicines Agency schedules Premafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10025MIG.

UNSPSC 51282940 Premafloxacin is a Commodity code that in recent state and local activity covers pharmaceutical procurement broadly — including naloxone, first aid supplies, and generic multi-source pharmaceuticals and over-the-counter products — rather than the specific antibiotic named in the code itself. State and local health agencies, fire departments, and cooperative purchasing alliances are the primary issuing bodies soliciting under this code. The work spans routine medical and pharmaceutical supply acquisition for emergency response, community health, and pharmacy benefit programs, with solicitations emphasizing compliance with FDA requirements, Good Manufacturing Practices, and Drug Supply Chain Security Act certification. Vendors must typically supply through authorized wholesale channels, maintain specified insurance coverage including commercial general liability and professional liability, and meet strict expiration-date and shelf-life requirements.

Recent activity shows geographically dispersed solicitation across Florida, Texas, and Minnesota. Representative opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the county health building (due July 26, 2023); the City of Tampa Fire Department Rescue Division's IFB for 169 line items of medical and first aid supplies with an estimated contract value of $700,000 and a March 13, 2026 due date, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas Health and Human Services Commission's Request for Information (RFI) on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (due April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, supplying through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC with awards effective July 1, 2026.